Age-related vision loss is one of the most common signs of getting older. By the time people reach their sixties, many notice that dimly lit restaurants become hard to navigate and menus require a phone flashlight. For a subset of older adults, that gradual decline progresses into age-related macular degeneration, one of the leading causes of blindness in the developed world. A team at the University of California, Irvine has spent years chasing one specific molecular thread behind that decline — and in a new study, they show it can be pulled in the opposite direction.
The thread is a gene called ELOVL2. It encodes an enzyme responsible for elongating certain long-chain polyunsaturated fatty acids, the fatty molecules that sit inside the membranes of photoreceptor cells in the retina. ELOVL2 is also one of the most reliable molecular markers of chronological aging in humans: as people get older, the gene’s regulatory region picks up chemical tags that quiet its activity. Less ELOVL2 means less of the fatty acids retinal cells need to function well. Less function means the aging eye many of us recognize from our own parents.
Skipping the enzyme, delivering the product
In earlier work, Dorota Skowronska-Krawczyk’s group at UC Irvine showed that directly boosting ELOVL2 activity in old mice raised levels of the omega-3 fatty acid DHA in the eye and improved vision. That was a proof of principle, but it required switching the enzyme back on — a delicate target in aging tissue. In the new study, published this month, the team tried something simpler: skip the enzyme entirely and deliver what it would have produced.
The researchers injected a specific very-long-chain polyunsaturated fatty acid, 24:5n-3, directly into the vitreous of aged mice. This molecule sits one step downstream of ELOVL2 in the biosynthesis pathway, which means supplying it bypasses the broken enzyme. The effect, reported in collaboration with groups at the Polish Academy of Sciences and the Health and Medical University Potsdam, was striking. Treated mice showed improved electrical responses in the retina, fewer age-related deposits under the retinal pigment epithelium, and molecular signatures that looked younger than those of untreated littermates of the same age.
A genetic link to AMD
The study also took a step closer to the clinic. In addition to the mouse work, the team looked at human genetic data and identified variants in ELOVL2 that correlate with faster progression of age-related macular degeneration. That is the kind of finding that opens two doors at once: a way to flag people who may be at higher risk of losing their sight, and a plausible target for slowing that loss before symptoms become severe.
Notably, the benefit in mice was specific. DHA supplementation, which has been sold as an eye-health add-on for years, did not reproduce the same effect on its own. The precise, longer-chain molecule directly downstream of ELOVL2 was what mattered. That is a useful correction to the general assumption that more omega-3 is simply better for aging eyes.
What this means and what it doesn’t
The work is still in mice, and the treatment was delivered by direct intravitreal injection, not an oral supplement. A pill or drop that achieves the same effect is not around the corner. But the study does two important things: it tightens the case that ELOVL2 is a genuine driver of retinal aging rather than just a marker of it, and it shows that the downstream chemistry is manipulable in a living animal. In ongoing collaborations with UC San Diego, Skowronska-Krawczyk’s group is also looking at whether similar lipid-based interventions could slow aging in the immune system, where ELOVL2 appears to play an unexpectedly broad role.
For now, the cleanest way to read the finding is this: the biology of aging is easier to move than it once looked, at least in this particular tissue, and at least in mice. Whether that translates to human eyes is the next experiment.